One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Cardio Diagnostics Holdings, Inc.
CDIO · NCM · Healthcare · Biotechnology
Current price
$1.69
52-week range
$0.97 - $7.91
Market cap
$5.00M
Balance sheet
Healthy
-438.08x Concerning
Net cash $5.22M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings, Inc. creates specialized blood tests that use genetics to help doctors assess a person's risk of heart disease. The money they make primarily comes from selling these tests to doctor's offices and other healthcare providers, which is important because it helps these providers offer better care and potentially prevent serious heart problems for their patients.
How the company got here
Cardio Diagnostics Holdings, Inc. was founded in 2017 with the goal of using cutting-edge science to help prevent heart attacks and other cardiovascular events. The company is focused on developing and selling specialized blood tests that look at a person's genetic and epigenetic information to predict their risk of heart disease. This approach aims to catch potential problems earlier than traditional methods, allowing for more proactive care. The company is headquartered in Chicago, Illinois.
What it actually does
Cardio Diagnostics develops and sells clinical tests that analyze a person's DNA and epigenetic markers (which are like switches that turn genes on or off) to assess the risk of developing cardiovascular diseases, such as coronary heart disease. These tests are designed to provide doctors with more detailed information to help manage patient care and potentially prevent serious cardiac events like heart attacks. The company's offerings include blood tests and a software platform that provides insights into cardiovascular risk.
Epi+Gen CHD Test
This is one of Cardio Diagnostics' main products, a clinical blood test designed to assess a person's risk of symptomatic coronary heart disease (CHD) over a three-year period. It uses a combination of genetic and epigenetic information from a blood sample to identify individuals who may be at higher risk for events like heart attacks. The goal is to help healthcare providers intervene earlier with lifestyle changes or treatments for patients identified as high-risk.
PrecisionCHD Test
The PrecisionCHD test is another key offering, integrating both epigenetic and genetic data from a blood sample. This test is specifically aimed at detecting coronary heart disease. By analyzing these biological markers, the test provides clinicians with a more precise understanding of a patient's cardiovascular health, aiding in the diagnosis and management of CHD.
Actionable Clinical Intelligence Platform
This platform serves as a tool for healthcare providers, offering new epigenetic and genetic insights to help them manage chronic conditions, particularly cardiovascular disease. It aims to translate complex biological data into practical information that doctors can use to make better treatment decisions for their patients. The platform supports improved chronic care management by providing deeper understanding of disease risk and progression.
CardioInnovate360 and HeartRisk
CardioInnovate360 is a service that supports the research and development of new treatments for cardiovascular diseases, acting as a 'research-use-only' solution for biopharmaceutical companies. HeartRisk is a software-as-a-service (SaaS) platform that provides intelligence on cardiovascular disease risk. These offerings cater to both healthcare providers and the pharmaceutical industry, supporting innovation and risk assessment in cardiovascular health.
What management is betting on now
Cardio Diagnostics' management is focused on commercializing its epigenetic and genetic testing solutions to improve the early detection and management of cardiovascular disease. They are targeting various healthcare providers, including telemedicine services, specialized clinics, and employer organizations, to adopt their diagnostic tools. The company's strategy revolves around demonstrating the clinical utility and economic value of their tests in preventing costly cardiovascular events and improving patient outcomes.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-1.18M
FY2024 Q4
$-1.40M
FY2025 Q1
$-1.41M
FY2025 Q2
$-1.59M
FY2025 Q3
$-1.56M
FY2025 Q4
$-1.36M
FY2026 Q1
$-1.56M
FY2026 Q2
$-1.34M
Revenue
$5.36K
Net income
$-1.50M
Diluted EPS
-0.51
Operating cash flow
$-1.34M
Free cash flow
$-1.34M
Fetching…
Sources
Revenue
$2.68K
Net income
$-1.79M
Diluted EPS
-0.63
Operating cash flow
$-1.56M
Free cash flow
$-1.56M
Fetching…
Sources
Revenue
$3.56K
Net income
$-1.47M
Diluted EPS
-0.79
Operating cash flow
$-1.36M
Free cash flow
$-1.36M
Fetching…
Sources
Revenue
$2.85K
Net income
$-1.71M
Diluted EPS
-0.98
Operating cash flow
$-1.39M
Free cash flow
$-1.56M
Fetching…
Sources
Revenue
$7.47K
Net income
$-1.68M
Diluted EPS
-0.97
Operating cash flow
$-1.57M
Free cash flow
$-1.59M
Fetching…
Sources
Revenue
$940.00
Net income
$-1.64M
Diluted EPS
-0.97
Operating cash flow
$-1.40M
Free cash flow
$-1.41M
Fetching…
Sources
Revenue
$4.51K
Net income
$-1.52M
Diluted EPS
0.01
Operating cash flow
$-1.39M
Free cash flow
$-1.40M
Fetching…
Sources
Revenue
$6.58K
Net income
$-1.41M
Diluted EPS
-0.06
Operating cash flow
$-1.16M
Free cash flow
$-1.18M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $1.69
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $5.2M - more cash than debt. Interest coverage -438.1x.
Net debt
$-5.22M
Interest coverage
-438.08x
Cardio Diagnostics Holdings, Inc. is healthier than 0 of 1 peers on balance-sheet leverage.
Healthy
Worse cushion
Baseline
Better cushion
CDIO
BASELINE
Cardio Diagnostics Holdings, Inc.
Total debt $369.70K Interest coverage -438.08x This is the baseline the peer rows are being compared against.
What you should know
The case for and against CDIO
0 Rewards
1 Risk
Rewards
Risks
-
Return on equity was -75.4% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-6.76x
P/B
0.67x
P/S
346.12x
EV/EBITDA
0.00x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
100.0%
Operating margin
-27,950.5%
Net margin
0.0%
ROE
-75.4%
ROA
-44.1%
Health
Liquidity and balance-sheet strength
Debt / equity
0.05x
Current ratio
17.15x
Quick ratio
15.56x
Total debt
$369.70K
Total cash
$5.59M
Growth
How the business has been compounding
Revenue TTM
$14.45K
Revenue 5Y CAGR
149.9%
EPS TTM
-2.91
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-5.66M
Free CF TTM
$-6.15M
FCF margin
-42,533.9%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—